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Objective: The objective of this study was to evaluate the safety and tolerance of increasing single and repeated (n  2)
doses of intramuscular naked plasmid DNA encoding for fibroblast growth factor (FGF) type 1 (NV1FGF) administered
to patients with unreconstructible end-stage peripheral arterial occlusive disease (PAD). The secondary objectives were to
determine the biologic activity of NV1FGF on hemodynamic and clinical parameters associated with improved perfusion.
Methods: Fifty-one patients with unreconstructible peripheral arterial occlusive disease with rest pain or tissue necrosis
underwent treatment with intramuscular NV1FGF. Increasing single (500, 1000, 2000, 4000, 8000, and 16,000 g)
and repeated (2  500, 2  l000, 2  2000, 2  4000, and 2  8000 g) doses of NV1FGF were injected into the
ischemic thigh and calf. Arteriography was performed before treatment and was repeated 12 weeks after treatment. Side
effects and serious adverse events were monitored. Measurements of plasma and urine levels were performed to evaluate
NV1FGF plasmid distribution. Serum FGF-1 was measured as an analysis of gene expression at the protein level.
Transcutaneous oxygen pressure, ankle brachial index, toe brachial index, pain assessment with visual analog scale, and
ulcer healing also were assessed. The safety results are presented for 51 patients, and the clinical outcomes are presented
for the first 15 patients (500 to 4000 g) who completed the 6-month follow-up study.
Results: NV1FGF was well tolerated. Sixty-six serious adverse events were reported; however, none were considered to be
related to NV1FGF. Four patients had adverse events that were possibly or probably related to the study treatment:
injection site pain, pain, peripheral edema, myasthenia, and paresthesia. No laboratory adverse events were related to the
study treatment. Two deaths remote from the treatment were considered not related. Biodistribution of plasmid was
limited and transient in plasma and absent in urine. No increase in the FGF-1 serum level was detected. A significant
reduction in pain (P < .001) and aggregate ulcer size (P < .01) was associated with an increased transcutaneous oxygen
pressure (P < .01) as compared with baseline pretreatment values. A significant increase in ankle brachial index (P < .01) was seen.
Conclusion: NV1FGF is well tolerated and potentially could be effective for the treatment of patients with end-stage limb
ischemia. Biologic parameters indicate improved perfusion after NV1FGF administration. Dose response is not yet
evident. The safety of NV1FGF and the magnitude of improvement observed in this study encourage further investiga-
tion with a placebo-controlled, double-blind clinical trial. (J Vasc Surg 2002;35:930-6.)
Patients with critical limb ischemia have a high risk of
limb loss and associated cardiovascular morbidity/mortal-
ity.1 Direct revascularization with autogenous vein for in-
frainguinal occlusive disease offers the best chance of suc-
cess and is the most durable procedure.2,3 However, in the
From the Temple University School of Medicinea; Gencell, Aventis
Pharmab; Hennepin County Medical Centerc; Atlanta Cardiovascular
Groupd; Washington Hospital Centere; Cornell Universityf; University of
Miamig; Watson Clinich; University of Tamperei; and Gencell, Aventis
Pharma.j
Funded through a Research Grant from Gencell, Aventis Pharma, Antony,
France.
Competition of interest: Drs Comerota and Throm have been paid a
consulting fee by Gencell, Aventis Pharma.
Presented at the Forty-ninth Annual Meeting of the American Association
for Vascular Surgery, Baltimore, Md, Jun 12-13, 2001.
Additional material for this article may be found online at www.mosby.
com/jvs.
Reprint requests: Anthony J. Comerota, MD, FACS, Department of Sur-
gery, Temple University School of Medicine, Broad & Ontario Streets,
Philadelphia, PA 19140.
Copyright © 2002 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2002/$35.00  0 24/6/123677
doi:10.1067/mva.2002.123677
930
absence of successful revascularization, the prognosis for
limb salvage and quality existence is poor. Psychologic
testing of such patients shows quality of life indices similar
to patients with critical or terminal malignant disease.4
Patients whose conditions are considered unrecon-
structible or in whom prior leg revascularization has failed
have a particularly poor prognosis, with 6-month amputa-
tion and mortality rates as high as 40% and 20%, respective-
ly.5-8
Therapeutic angiogenesis9 is a new treatment strategy
designed to improve collateral blood vessel formation with
stimulation of neovascularization through the expression of
angiogenic growth factors. Fibroblast growth factors
(FGFs) are some of the earliest angiogenic growth factors
studied. The FGF family of growth factors acts on endo-
thelial cells, smooth muscle cells, and fibroblasts via an
interaction with specific receptors on the cell surface. FGF
receptors have been identified on a variety of tissues, in-
cluding brain, bone matrix, kidney, retina, heart, skeletal
muscle, and others.
The gene encoding acidic FGF-1 was shown to activate
endothelial cell migration and proliferation in vitro. FGF-1
induced angiogenesis in vivo when injected as a purified
protein or when expressed from its DNA coding sequence
after insertion in an expression vector.
The therapeutic effect of FGF-1 was studied in a rabbit
model of hind limb ischemia.10 Daily intramuscular injec-
tion of recombinant FGF-1 (4 mg) for a period of 10 days
led to a significant improvement in the ischemic limb, on
the basis of angiographic and calf blood pressure assess-
ments. Nabel et al11 showed that recombinant FGF-1
promotes intimal hyperplasia and angiogenesis in arteries in
vivo. In addition to its proangiogenic properties, FGF-1
showed cardioprotective and antiapoptotic effects in car-
diac ischemia-reperfusion models.12,13 A similar effect was
also found in skeletal muscle.14 Schumacher et al15 re-
ported the first clinical results of FGF-1 recombinant pro-
tein to induce neoangiogenesis in the ischemic myocar-
dium of patients with coronary artery disease.
Gene transfer offers a seductive alternative strategy to
delivery of locally sustained levels of therapeutic protein.
Subcutaneous administration of a replication deficient re-
combinant adenovirus expressing FGF-1 fused to a heter-
ologous secretion signal (from FGF-4) resulted in angio-
genesis in mice at the site of injection.16 Intramyocardial
injection of the FGF-1 adenoviral vector before coronary
artery ligation could induce angiogenesis, thereby reducing
the area of risk in a rabbit model of myocardial infarction.17
Catheter-mediated transfer of a plasmid encoding a natu-
rally occurring truncated form of human FGF-1 fused to a
heterologous secretion signal was shown to promote angio-
genesis in an animal model of experimental hind limb
ischemia.18 The intramuscular injection of naked plasmid
DNA into ischemic muscle of patients with end-stage pe-
ripheral arterial occlusive disease (PAD) was thought to be
the preferred route for therapeutic angiogenesis with FGF-
1.19
In prior studies that evaluated vascular endothelial
growth factor (VEGF), angiogenesis appeared to be re-
stricted to areas of ischemia. This result might be explained
with the upregulation of VEGF receptors in response to
hypoxic skeletal muscle.20-22 Although the intraarterial
delivery of angiogenic factors has shown evidence of im-
proved perfusion, these observations of benefit or evidence
of neovascularization have been inconsistent.23-25 The in-
tramuscular injection of angiogenic factors into animal
models of coronary and hind limb ischemia has shown
more consistent evidence of neovascularization.26
The muscles of the patient with advanced lower ex-
tremity ischemia are hypoxic, which may assist in the trans-
fer of naked DNA encoding for FGF-1 (NV1FGF) when
delivered intramuscularly because transfection efficiency
has been shown to be increased when the injected skeletal
muscle is ischemic.22 This effect also has been shown in the
ischemic myocardium, where the uptake and retention of
tracer labeled growth factor is low after intracoronary in-
jection, whereas uptake and retention are improved with
intramuscular (intramyocardial) injection.27,28
The primary purpose of this first in human study is to
evaluate the safety and tolerance of increasing doses of
intramuscular NV1FGF in patients with end-stage PAD.
The secondary objectives are to evaluate markers of bio-
logic activity of NV1FGF on improved arterial perfusion.
METHODS
Protocol summary. Patients with unreconstructible
grade II category 4 ischemia (ischemic rest pain) and grade
III category 5 ischemia29 (ulceration or tissue necrosis)
underwent treatment with increasing doses (500 g to
16,000 g) of intramuscular injection of NV1FGF. Injec-
tions were given into the distal thigh and distal leg muscles.
The protocol was reviewed and approved by the insti-
tutional review board of each participating institution in the
United States and Finland. Patients were entered into the
study after signing of informed consent. The ischemic rest
pain or trophic lesions had to have been present for at least
28 days with no signs of improvement and no reduction in
ulcer size or depth. This timeline applied to the first 15
patients but was amended to 14 days to reduce suffering
and to improve patient eligibility. Objective evidence of
severe PAD was necessary, with an ankle brachial index
(ABI) of less than 0.4, a resting toe brachial index (TBI) of
less than 0.3, or metatarsal pulse volume recording (PVR)
flat or barely pulsatile in the diseased limb on two consec-
utive examinations performed at least 2 weeks apart. Arte-
riography was performed and was necessary to confirm
arterial occlusion. All patients of 18 years of age or more
with severe, unreconstructible PAD were considered po-
tential candidates. However, entry into this study was re-
stricted to those who had no history of malignant disease,
no suspicious findings on chest x-ray, mammography, Pa-
panicolaou smear, and normal prostate specific antigen, and
no proliferative retinopathy. The patients entered into the
study had a complete history and physical examination, an
ophthalmologic examination, a 12-lead electrocardiogram,
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and routine laboratory blood tests, including complete
blood cell count and biochemistry (electrolytes, blood urea
nitrogen/creatinine, and liver enzymes).
The effectiveness of NV1FGF was evaluated with clin-
ical and biologic markers correlated with improved tissue
perfusion. Complete arteriography visualizing the entire
arterial tree from the level of the abdominal aorta to the
pedal arteries in the foot was performed within 1 month
before study entry and was repeated 12 weeks after treat-
ment.
Pressure measurements. For patient inclusion and
follow-up examination, the following measurements were
used: ankle systolic pressure in the dorsalis pedis and pos-
terior tibial arteries (systolic at rest), brachial blood pressure
(systolic at rest), great toe pressure (systolic at rest), ABI,
and great TBI obtained at baseline and at weeks 2, 3, 4, 8,
12, and 24.
Pulse volume recording. The metatarsal PVR was
used to evaluate patients with clinical signs of severe isch-
emia whose ABI appeared to be falsely elevated. The PVR
measurement was used for baseline inclusion criteria only,
assisting the evaluation of patients with calcified vessels and
artifactually elevated pressures.
Transcutaneous oximetry. Transcutaneous monitor-
ing of skin tissue oxygen is a noninvasive technique that
measures blood flow beneath a sensor that is placed on the
skin surface, which has been standardized and reported.30
Transcutaneous oximetry (TcPO2) measurements were ob-
tained at baseline and at weeks 2, 3, 4, 8, and 12 with the
patient supine and were recorded after 30 minutes of
continuous monitoring. Changes from baseline were re-
corded for each patient and compared for each time point.
Pain assessment. Pain assessment was evaluated with
a self-administered visual analog scale at baseline and at
weeks 2, 3, 4, 8, 12, and 24 after treatment. Changes from
baseline were used to chart patients’ ongoing perception of
pain and were compared at each time point.
Ulcer healing. The statuses of all patient ulcers were
evaluated at baseline and followed at weeks 2, 3, 4, 8, 12,
and 24 posttreatment visits. Each ulcer was identified at
baseline, and any newly formed ulcers were identified dur-
ing the follow-up study. Ulcers were graded as to physical
location, size, depth, and type.
To understand the overall impact of NV1FGF on ulcer
area, the aggregate ulcer size was evaluated over time. With
the intent of maintaining the patient ulcer size as the unit of
analysis, an aggregate ulcer score (units in cm2) was calcu-
lated for each patient at each protocol-specified visit, which
is the sum of all ulcer areas. As with other biologic activity
parameters, the variable analyzed was the aggregate percent
change from baseline, with improvement denoted as a
negative score.
NV1FGF is a plasmid harboring an optimized expres-
sion cassette inserted in a novel plasmid backbone designed
with conditional replication (pCOR).31 A fusion gene be-
tween human fibroblast interferon secretion signal pep-
tide32 and the naturally occurring truncated form of human
FGF-1 from amino acids 21 to 15433 was placed into a
pCOR plasmid. This pCOR backbone is devoid of any
antibiotic resistance gene. Plasmid selection relies on a
suppressor transfer RNA gene in the autotrophic recipient
strain. Maintenance of high copy number and strictly lim-
ited host range of the plasmid were obtained with the R6Ky
origin of replication, which requires the protein to initiate
replication. The sequence coding for this protein is not
usually found in bacteria but was artificially inserted into
the genome of the chosen host strain. Thus, plasmid po-
tential dissemination is greatly limited. As an additional
beneficial aspect, the pCOR backbone is small (1 Kbp) as
compared with conventional backbone (2 to 2.5 Kbp), thus
reducing by half the amount of unwanted bacterial DNA
injected into the patient.
Naked plasma DNA encoding fibroblast growth
factor type 1 levels. To evaluate plasmid biodistribution
after intramuscular injection, blood samples were drawn at
each protocol visit and analyzed with real-time polymerase
chain reaction (Taqman, ABI, Foster City, Calif) by Biore-
liance.
Fibroblast growth factor type 1 levels. Blood sam-
ples were drawn at each protocol visit to evaluate FGF-1
serum levels. FGF-1 levels were used as a direct marker of
gene expression. Serum levels of FGF-1 were measured
with enzyme-linked immunosorbent assay (EIA kit Quan-
tikine human FGF-1, R & D Systems Inc, Minneapolis,
Minn) methodology and reported by the Institute Armand
Frappier (Laval, Canada).
Statistical analysis. The primary response variable was
safety assessment, including adverse events, physical exam-
ination, ophthalmologic examination, vital signs, electro-
cardiogram, and laboratory determinations. The analysis
was descriptive. No formal statistical testing was applied to
each dose cohort because the number of patients per dose
was too small.
The secondary goal was to evaluate noteworthy im-
provements in patient status with comparison of the patient
pretreatment assessment (baseline) with the assessment
performed after study treatment (protocol weeks 2 to 24).
This “with-in” patient comparison was assessed with a
with-in t test (or paired Student t test). The Wilcoxon
signed ranked statistic also was used to evaluate the popu-
lation mean hypothesis. Although this nonparametric test is
not presented in this manuscript, the Wilcoxon signed
ranked result was consistent with the with-in t test conclu-
sion.
For detailed methods, see Appendix I (online only).
RESULTS
Fifty-one patients underwent treatment and analysis for
safety (Table I). Safety results are presented for these 51
patients and their demographics listed in Table II. An
interim analysis of all patients (500 to 4000 g) who
completed the 6-month follow-up study (n  15) was
available for evaluation of markers of biologic activity and
clinical outcome measures.
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Safety
Serious adverse events. A total of 66 serious adverse
events (SAEs) were reported in 29 patients. Among the 66
SAEs, eight were reported during the screening period
(before NV1FGF administration). No event was assessed as
likely related to study treatment. Six events (hemoptysis,
toxic metabolic encephalopathy, left foot toes 1 to 3 frank
gangrene, right cellulitis and enlargement of leg wound,
non-Q wave myocardial infarction, and presumed sudden
cardiac death) were considered as unlikely related. Two
patients died during the course of the study. One patient
with toxic metabolic encephalopathy died 29 days after
NV1FGF administration. The death, described as caused
by withdrawal of hemodialysis, was considered as unlikely
related to NV1FGF. A patient with underlying severe cor-
onary artery disease with decreased left ventricular function
who had refused internal defibrillator placement died of
presumed sudden cardiac death. The medical examiner
declared death was the result of natural causes, possibly
cardiac related. Three events (hemoptysis, left foot toes 1 to
3 frank gangrene, and right cellulitis and enlargement of leg
wound) were considered as unlikely caused by NV1FGF.
The remaining SAEs were assessed as not related.
For itemized SAEs see Appendix II (online only).
Adverse events. The intramuscular administration of
NV1FGF was well tolerated. Four patients had adverse
events possibly or probably related to the study treatment:
injection site pain, pain, peripheral edema, myasthenia, and
paresthesia. All were single occurrence. No laboratory ad-
verse events were related to the study treatment.
Biologic outcomes
Plasma naked plasmid DNA encoding fibroblast
growth factor type 1. NV1FGF biodistribution in plasma
was limited and transient. The maximal amount of
NV1FGF detected was observed for one patient in the
2000 g group 1 week after study treatment administra-
tion: 994 copies/10 L plasma extract. Another patient
(4000 g dose level) had 681 copies 1 week after treat-
ment. Four more patient plasma samples were negative 4
weeks after treatment.
Urine naked plasmid DNA encoding fibroblast
growth factor type 1. NV1FGF was not detected in urine
for single doses tested between 500 and 4000 g.
Serum fibroblast growth factor 1. Only one patient
had serum with positive levels of FGF-1 (before and after
treatment with NV1FGF). All other tested patients had
serum negative for FGF-1.
Clinical Outcomes
Pain scale. All doses of NV1FGF showed a steady
decrease in pain (improvement) during the 6 months of the
study. Noteworthy improvement was seen in patient status
during the duration of the trial, showing significant de-
creases in pain at all protocol visits (Fig 1). Patients showed
a decrease in mean pain at all study visits with significant
decreases between weeks 8 and 24 (week 8, P .001; week
12, P  .0004; and week 24, P .0026).
Table II. Demographics of 51 patients receiving
NV1FGF
Single dose
(n  27)
Repeat dose
(n  24)
Total
(n  51)
Age (y) 66 67 67 (28-86)
Gender
Male 68% 71% 69%
Female 32% 29% 31%
Race
White 89% 83% 86%
African American 11% 8% 10%
Hispanic 0% 8% 4%
Height (cm) 171 168 170
Weight (kg) 80 80 80
Ischemia
Grade II category 4 48% 50% 49%
Grade III category 5 52% 42% 47%
Grade III category 6 0% 8% 4%
Smoking status
Never 37% 17% 28%
Current/previous 67% 83% 72%
Diabetes 41% 42% 41%
Hypertension 56% 71% 63%
Hyperlipidemia 48% 58% 53%
Heart disease 52% 71% 61%
Cerebrovascular disease 33% 29% 31%
COPD 15% 17% 16%
Prior vascular procedures
Failed bypass 44% 38% 41%
Balloon angioplasty 19% 33% 25%
Skin graft 4% 4% 4%
Major contralateral
amputation (AKA/BKA)
11% 24% 16%
COPD, Chronic obstructive pulmonary disease; AKA, above-knee amputa-
tion; BKA, below-knee amputation.
Table I. Patient enrollment by dose of NV1FGF
Total NV1FGF dose (g)
No. of patients
Single
administrations
Repeated
administrations
500 3 –
1000 3 3 (2  500 g)
2000 3 3 (2  1000 g)
4000 6 6 (2  2000 g)
8000 6 6 (2  4000 g)
16,000 6 6 (2  8000 g)
Fig 1. Pain assessment with visual analog scale after intramuscular
NV1FGF (baseline  100%).
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Transcutaneous oximetry pressure. TcPO2 was eval-
uated as a change from baseline. All doses showed increases
in TcPO2 during the 3 months of the study (Fig 2), with
significant increases at week 8 (P  .035) and at week 12
(P  .0012). TcPO2 was not evaluated at 6 months.
Ankle brachial index. Because all patients in this anal-
ysis had severe arterial occlusive disease, patients with an
ABI of 1.0 or more were excluded from this analysis (two
patients). The variable used in this analysis was the ABI
change from baseline. No significant difference was shown
at any protocol visit. However, results showed a significant
increase (improvement) in mean ABI at weeks 8 and 12
(Fig 3).
Toe brachial index. The TBI was evaluated as a
change from baseline, with any positive pressure denoting
improvement. No significant improvement was seen from
baseline to any subsequent visit.
Ulcer healing. Ulcer healing was evaluated in nine
patients who entered the study with at least one preexisting
ulcer. No patient had complete ulcer healing, defined as all
ulcers healed and remaining healed until the end of the
study. Three patients had complete healing of at least one
ulcer that remained healed until the end of the study.
Evaluation of aggregate ulcer size shows a progressive
reduction over time (Fig 4), with 68% of the surface area of
all ulcers healed at the last protocol visit (P  .002)
DISCUSSION
A new therapeutic option is on the horizon for patients
with critical limb ischemia. Gene therapy that stimulates
new blood vessel growth, thereby promoting collateral
circulation to the ischemic tissue, is welcomed with enthu-
siasm. However, understanding the regulation of new
blood vessel growth in human health and disease mandates
that this new treatment option proceed with appropriate
caution.
Angiogenesis is well regulated during reproduction,
development, and wound repair, with periods of maximal
stimulation followed by complete inhibition. A number of
pathologic conditions are the result of persistently upregu-
lated (unregulated) angiogenesis, such as arthritis, ocular
diseases, and growth of neoplasms and their metastases.
Therefore, establishment of the safety of gene therapy
stimulating angiogenesis must assume priority and temper
enthusiasm for early widespread therapy. Because of these
concerns, the protocol adopted in this phase I trial was
restricted to patients who had established end-stage lower
extremity PAD, no history of malignant disease, no suspi-
cious findings on chest x-ray, mammography, Papanico-
laou smears, and normal prostate specific antigen, and no
proliferative retinopathy.
The results of treatment with intramuscular NV1FGF
of 51 patients have suggested that this angiogenic com-
pound is safe. No SAEs were attributed to NV1FGF. Two
deaths occurred remote from treatment. The mortality rate
observed in this patient cohort followed to date was actually
lower than anticipated, considering the severity of the
lower extremity ischemia and the associated comorbidities
of this patient group.3,34
No increase in FGF-1 serum levels were observed after
NV1FGF intramuscular administration despite the use of a
sensitive enzyme-linked immunosorbent assay specifically
set up in collaboration with research and development
systems for circulating FGF-1 evaluation. Animal data have
shown that intramuscular injection of NV1FGF does not
lead to detectable FGF-1 in serum, whereas FGF-1 immu-
nopositive fibers can be detected on histologic sections.
These results suggest that FGF-1 protein is restricted to the
injected muscle. Absence of circulating FGF-1 is expected
to provide a safety advantage over factors such as VEGF-A
that have been described to leak into the circulation and
lead to distant edema.19
FGF-2 has been described as able to induce expression
of VEGF in vascular endothelial cells through autocrine
Fig 2. Foot TcPO2 (mm Hg; mean) after intramuscular
NV1FGF (change from baseline).
Fig 3. Mean ABI after intramuscular NV1FGF.
Fig 4. Ulcer healing. Aggregate ulcer size after intramuscular
NVLFGF.
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and paracrine mechanisms.35 NV1FGF expression of
FGF-1 possibly leads to induction of VEGF-A expression.
Additional patients with higher doses of NV1FGF need to
be tested to confirm this hypothesis.
The clinical markers of biologic activity showed im-
provement after administration of NV1FGF. Patients in
each dose cohort of NV1FGF showed a decrease in isch-
emic rest pain during the 6 months of patient follow-up
study. Likewise, patients with ulceration also showed ulcer
healing throughout the course of the study.
Although a statistically significant increase in ABI (P
.005) was seen, the absolute increase in mean ABI (0.08)
failed to satisfy the recommended outcome criteria used to
assess the results of operative or endovascular revasculiza-
tion procedures.36 Because most of these patients had
ischemia caused by multilevel arterial occlusive disease and
because the neovascularization stimulated by angiogenesis
involved the growth of vessels in the 150 to 200 micron
range, it might be optimistic to expect meaningful increases
in perfusion pressures at the ankle via collaterals of this
diameter. However, observations suggest that NV1FGF-
stimulated angiogenesis was therapeutic. A reduction was
seen in ischemic rest pain to a point that patients were no
longer taking analgesics and were able to sleep an entire
night in a supine position. Ischemic ulcers showed healing,
and the aggregate ulcer size was reduced by 68% at study
end.
Isner and colleagues37 were the first to study therapeu-
tic angiogenesis in humans with severe lower extremity
ischemia. Their initial report of clinical efficacy followed the
delivery of 2000 g human plasmid phVEGF165 delivered
via a hydrogel polymer coating of an angioplasty balloon to
the distal popliteal artery. The authors observed an increase
in collateral vessels at the knee, midtibial, and ankle levels
and increased blood flow shown with intraarterial Doppler
scan.
The same group subsequently reported their experi-
ence with intramuscular gene transfer of 4000 g of naked
plasmid DNA encoding the same isoform of VEGF
(phVEGF165).19 They showed significant improvement in
the ABI (P  .02), which also exceeded the threshold for
reporting standards of improved perfusion. Newly visible
collateral blood vessels were documented with contrast
arteriography and improved perfusion with magnetic reso-
nance angiography. They likewise observed healing of isch-
emic ulcers in four of seven limbs. Tissue specimens ob-
tained 10 weeks after gene therapy from a patient who
underwent amputation showed foci of proliferating endo-
thelial cells with immunohistochemistry. Serum VEGF lev-
els were elevated 5 to 6 weeks after treatment.
More similarities than differences appear to exist be-
tween these two reports after intramuscular NV1FGF and
phVEGF165. Both reports showed improved ulcer healing
and reduced ischemic rest pain. The differences observed in
hemodynamic outcome, particularly the ABI, may be re-
lated to single observer versus multiple observer recordings,
with greater interobserver variability than intraobserver
variability.
Notable differences are found between the effects of
VEGF-A and FGF-1. VEGF-A, also known as vascular
permeability factor, is mitogenic only for vascular endothe-
lial cells. In contrast, FGF-1 has more wide-ranging mito-
genic potential. FGF-1 stimulates the growth of endothe-
lial cells and is mitogenic for smooth muscle cells and
fibroblasts, and for certain epithelial cells. As a result of the
potential mitogenic effect on smooth muscle cells, theo-
retic risk of neointimal fibroplasia exists. Short-term studies
are not sufficient to exclude this possible risk. Tabata,
Silver, and Isner18 studied intraarterial gene transfer of
plasmid linked acidic FGF. Augmented collateral flow was
shown in the ischemic limb; however, no histologic evi-
dence was found of neointimal thickening when compared
with animals treated with the Lac Z control.
FGF also promotes neurite outgrowth. In certain con-
ditions, it acts as a differentiating and maintenance factor
for nerves.38,39 Whether this effect is beneficial for patients
with ischemic rest pain needs further investigation.
This study appears to begin to answer the question: “Is
therapeutic angiogenesis safe for clinical use?” No early
SAEs were reported to be possibly or probably related to
NV1FGF. Longer-term observation is necessary to ensure
that neovascularization does not develop in areas that were
not supposed to be targeted by the angiogenic intervention
and that a tumorigenic effect is not observed. This occur-
rence appears unlikely because plasmid biodistribution was
limited and transient and because no circulating levels of
FGF-1 were detectable.
An important question is: “How long does the im-
proved perfusion persist?” There appear to be consistent
observations of possible stimulation of improved perfusion
with therapeutic angiogenesis. However, the durability of
this early benefit remains to be determined. Anecdotally,
the first patient treated in this study with single dose 500g
NV1FGF obtained complete pain relief and had all isch-
emic ulcers healed. Ambulation and quality of life signifi-
cantly improved. This beneficial effect lasted almost 1 year,
after which time significant deterioration occurred with
recurrence of ischemic rest pain and ischemic ulcers. Future
studies should address the issue of maintenance angiogen-
esis in patients with initially beneficial effects.
Therapeutic angiogenesis with gene transfer tech-
niques has significant potential for the treatment of patients
with severe lower extremity ischemia and may provide a
new therapeutic option for patients who are not candidates
for standard revascularization. The intramuscular adminis-
tration of NV1FGF was safe and well tolerated without any
SAEs attributed to its use. Markers of biologic activity
uniformly showed improved perfusion. The true magni-
tude of improvement needs critical analysis from a double-
blind, placebo-controlled trial.
We thank Ms Ebony Mason and Dr Dominique Note-
let for their assistance with manuscript preparation and Drs
Abdu Merzuki and Max Arella for enzyme-linked immuno-
sorbent assay analysis.
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